Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10381
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10381 is an orally administered, small molecule inhibitor targeting Src homology region 2-containing protein tyrosine phosphatase (SHP2), also known as protein tyrosine phosphatase non-receptor type 11. By binding to and inhibiting SHP2, HS-10381 disrupts SHP2-mediated signaling pathways such as the MAPK pathway, which are implicated in tumor cell proliferation and survival. The drug is being developed primarily for the treatment of advanced solid tumors that have not responded to standard therapies. Its mechanism of action may also enhance immune responses against tumors by increasing MHC class I expression on cancer cells. The developer and manufacturer is Jiangsu Hansoh Pharmaceutical. As of early 2025, it is in Phase I clinical trials in China for patients with advanced solid tumors.
- Other names
- SHP2 inhibitor HS-10381SHP-2 inhibitor HS-10381SHP 2 inhibitor HS-10381
02
Targets
PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on HS-10381.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10381.